Industry

血液检测创业公司 Helios 获 230 万美元种子轮融资

Why we picked it

一家 YC 系的血液检测公司拿到了 230 万美元融资,方向是用一滴血加 AI 算你的器官健康和患病风险。它总被拿来跟 Theranos 比,但走的是蛋白质组学路线。关注 AI 在医疗诊断落地的人可以看看。

Y Combinator 孵化的血液检测创业公司 Helios 完成 230 万美元种子轮融资。此前多位潜在投资人将其商业计划和 Theranos 相提并论,引发警惕。

Image · The Information
Body

与 Theranos 的区别在于技术路线:Helios 采用蛋白质组学(proteomics)结合 AI 模型,仅凭一滴血就能预测器官健康状况和未来患病风险。

血液检测赛道因 Theranos 事件长期笼罩阴影,Helios 能否用可验证的蛋白质组学数据重建投资人信任,是这轮融资之后的核心考验。

Original · The Information

Exclusive: Helios, a Y Combinator blood-testing startup, raised $2.3 million in seed funding after several prospective investors compared its pitch to Theranos.

The difference is that Helios uses proteomics and AI to predict organ health and future disease risk from a single drop of blood.

Full story: https://t.co/o6RaMRTrDx

Industry Coordinates & Source Verification

This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include Helios, Y Combinator, medical AI, proteomics.

Source attribution: curated from The Information (@theinformation).